Misplaced Pages

Foselutoclax

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is the current revision of this page, as edited by Boghog (talk | contribs) at 13:58, 22 January 2025 (created drug stub). The present address (URL) is a permanent link to this version.

Revision as of 13:58, 22 January 2025 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Pharmaceutical compound
Foselutoclax
Clinical data
Other namesUBX1325
Identifiers
IUPAC name
  • 5-(4-chlorophenyl)-2-methyl-4-amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylamino]phenyl]piperazin-1-yl]phenyl]-1-propan-2-ylpyrrole-3-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC53H59ClF3N6O10PS3
Molar mass1159.69 g·mol
3D model (JSmol)
SMILES
  • CC1=C(C(=C(N1C(C)C)C2=CC=C(C=C2)Cl)C3=CC(=CC=C3)N4CCN(CC4)C5=CC=C(C=C5)NS(=O)(=O)C6=CC(=C(C=C6)N(CCN7CCC(CC7)OP(=O)(O)O)CSC8=CC=CC=C8)S(=O)(=O)C(F)(F)F)C(=O)O
InChI
  • InChI=InChI=1S/C53H59ClF3N6O10PS3/c1-35(2)63-36(3)49(52(64)65)50(51(63)37-12-14-39(54)15-13-37)38-8-7-9-43(32-38)62-30-28-61(29-31-62)42-18-16-40(17-19-42)59-77(71,72)46-20-21-47(48(33-46)76(69,70)53(55,56)57)58-41(34-75-45-10-5-4-6-11-45)22-25-60-26-23-44(24-27-60)73-74(66,67)68/h4-21,32-33,35,41,44,58-59H,22-31,34H2,1-3H3,(H,64,65)(H2,66,67,68)/t41-/m1/s1
  • Key:FSZILRQCEAUYPL-VQJSHJPSSA-N

Foselutoclax is an investigational new drug that is being evaluated for the treatment of age-related eye diseases, particularly diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Developed by Unity Biotechnology, this senolytic compound acts as a potent inhibitor of Bcl-xL, a protein that senescent cells rely on for survival. Foselutoclax is designed to selectively eliminate senescent cells in the retina, potentially addressing the underlying causes of vision loss in these conditions.

References

  1. Crago SM (22 June 2023). "Design for Phase 2B ASPIRE Study of UBX1325 for DME announced by UNITY". Modern Retina. Archived from the original on 13 August 2024.
  2. Macha N, Yu M, Sapieha P, Klier S, Ghosh A, White L, et al. (September 2024). "Multifocal Electroretinography Changes after UBX1325 (Foselutoclax) Treatment in Neovascular Age-Related Macular Degeneration". Journal of Clinical Medicine. 13 (18): 5540. doi:10.3390/jcm13185540. PMC 11433175. PMID 39337030.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Foselutoclax Add topic